2023 Approvals

OJJAARA: A New Treatment for Myelofibrosis Approved by the FDA on September 15, 2023

OJJAARA: A New Treatment for Myelofibrosis Approved by the FDA on September 15, 2023

What is OJJAARA prescribed for?  OJJAARA is prescribed to treat intermediate or high-risk myelofibrosis in adults with anemia.  What is the name of the drug and what does it do? OJJAARA, pronounced oh-JAR-uh, (generic name: momelotinib) is a medication approved on September 15, 2023, for the treatment of adults with intermediate or high-risk myelofibrosis,...

APHEXDA: A New Frontier in Multiple Myeloma Treatment Approved by the FDA on September 8, 2023

APHEXDA: A New Frontier in Multiple Myeloma Treatment Approved by the FDA on September 8, 2023

What is APHEXDA prescribed for?  APHEXDA is used in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. What is the name of the drug and what does it do? APHEXDA , pronounced ah fex’ dah, (generic name: motixafortide) is a...

FDA Approves VEOPOZ on August 18th 2023: A New Treatment for CHAPLE Disease

FDA Approves VEOPOZ on August 18th 2023: A New Treatment for CHAPLE Disease

What is VEOPOZ prescribed for?   VEOPOZ is prescribed to treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. What is the name of the drug and what does it do? The drug, VEOPOZ, pronounced VEE-oh-poz, (generic name: pozelimab-bbfg)is an innovative treatment recently approved by the FDA to...

FDA Approves ORSERDU for Advanced Breast Cancer on January 27, 2023

FDA Approves ORSERDU for Advanced Breast Cancer on January 27, 2023

What is ORSERDU prescribed for?   For treatment of postmenopausal women or adult men, with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy What is the name of the drug and what does it do?  ORSERDU (generic name: elacestrant), pronounced...

FDA Approves Sohonos for Fibrodysplasia Ossificans Progressiva on August 16, 2023

FDA Approves Sohonos for Fibrodysplasia Ossificans Progressiva on August 16, 2023

What is Sohonos prescribed for?   Sohonos is prescribed to reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva. What is the name of the drug and what does it do? Sohonos, pronounced so-ho-nos, (generic name:...